Foghorn Payables Turnover from 2010 to 2024

FHTX Stock  USD 7.79  0.27  3.59%   
Foghorn Therapeutics Payables Turnover yearly trend continues to be fairly stable with very little volatility. Payables Turnover is likely to outpace its year average in 2024. Payables Turnover is a liquidity ratio that shows how quickly Foghorn Therapeutics pays off its suppliers by dividing total purchases by average accounts payable. View All Fundamentals
 
Payables Turnover  
First Reported
2010-12-31
Previous Quarter
17.52220447
Current Value
18.4
Quarterly Volatility
7.01276279
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 7.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Payables Turnover Growth Pattern

Below is the plot of the Payables Turnover of Foghorn Therapeutics over the last few years. It is a liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable. Foghorn Therapeutics' Payables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Payables Turnover10 Years Trend
Slightly volatile
   Payables Turnover   
       Timeline  

Foghorn Payables Turnover Regression Statistics

Arithmetic Mean3.72
Geometric Mean0.45
Coefficient Of Variation188.54
Mean Deviation5.39
Median0.19
Standard Deviation7.01
Sample Variance49.18
Range18.3964
R-Value0.65
Mean Square Error30.67
R-Squared0.42
Significance0.01
Slope1.02
Total Sum of Squares688.50

Foghorn Payables Turnover History

2024 18.4
2023 17.52
2022 0.003552
2021 1.97
2020 15.68
2019 0.52

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Payables Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Payables Turnover 17.52  18.40 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.